Live Feeds
● TRACKER Updated 26d ago · 9 sources tracked

After Moderna stock surge of 177% on cancer drug breakthrough, here's what Wall Street thinks happens next

Moderna's stock jumped 177% after announcing a breakthrough in its cancer vaccine trial, with the company's stock soaring to a 52-week high. The vaccine, developed in partnership with Merck, showed promise in a late-stage trial. This news has sparked speculation about the potential impact on the cancer treatment market.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (11)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Moderna's cancer vaccine shows promise in late-stage trial.
  • ✓ Moderna stock surged 177% after announcing cancer vaccine breakthrough.
  • ✓ The vaccine was developed in partnership with Merck.
  • ✓ Moderna's mRNA technology has potential for use in oncology.
🛡️ Source Corroboration: 9 independent reporting domains (90% confidence) ⏱ Read time: ~2 min

What changed

Moderna's stock price increased by 177% following the announcement of the cancer vaccine breakthrough, with multiple sources reporting on the surge.

Live updates

  1. Moderna stock surges on cancer vaccine breakthrough

    Moderna's stock jumped 177% after announcing a breakthrough in its cancer vaccine trial, with the company's stock soaring to a 52-week high. The vaccine, developed in partnership with Merck, showed promise in a late-stage trial. This news has sparked speculation about the potential impact on the cancer treatment market.

    Why it matters

    The breakthrough has significant implications for the future of cancer care, with potential for a new wave of cancer vaccines. Moderna's mRNA technology has already been successful in COVID-19 vaccines, and this development could mark a major expansion into oncology. The company's stock surge has also led to a substantial loss for short sellers.

    What is confirmed

    • Moderna's cancer vaccine shows promise in late-stage trial.
    • Moderna stock surged 177% after announcing cancer vaccine breakthrough.
    • The vaccine was developed in partnership with Merck.
    • Moderna's mRNA technology has potential for use in oncology.

    What to watch next

    • Future trial results
    • FDA approval process
    • Market impact on cancer treatment
    Sources used for this update (11)
    1. CNBC — Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 90%
    2. Bloomberg.com — Moderna’s 160% Surge Burns Shorts in ‘Painful’ $5 Billion Loss
    3. Reuters — Moderna, Merck breakthrough could usher in wave of cancer vaccines
    4. CBS News — Doctors explain how Moderna's melanoma mRNA vaccine could fight deadliest form of skin cancer
    5. Yahoo Finance — Why Did MRNA, MRK, TGT Stocks Jump To 52-Week Highs Today?
    6. The New York Times — From Covid to Cancer: How Moderna’s Stock Jumped 177% in a Day
    7. Yahoo Finance — After Moderna stock surge of 177% on cancer drug breakthrough, here's what Wall Street thinks happens next
    8. Barron's — Why Moderna Stock’s Historic Surge Is a Big Lesson for Markets
    9. Yahoo Finance — Moderna (MRNA) Is Up 173.9% After First Successful Phase 3 Individualized mRNA Cancer Therapy Trial - What's Changed
    10. Fierce Biotech — Merck-Moderna cancer vaccine win spurs stock jump, speculation of Keytruda-like impact
    11. The Boston Globe — What Moderna’s vaccine trial results might mean for the future of cancer care
    confidence 90%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community